Clinical Trial Search

Primary: Improvement of Pain. — 3 score on a scale (0-10)

Primary: Feasibility - Pain Consultation — 29 Participants

Primary: Average Pain Intensity Score — 1.192; 1.304 units on a scale

Primary: Analgesic Adherence-patient — 0.66; 0.67 proportion (0-1), higher is better — p=.43

Primary: Prescription Pattern of Analgesics (Opioid or Non-opioid) — 37.27; 11.33; 51.40 percentage of patients

Primary: Change in Pain Intensity — -1.61; -1.35 score on a scale — p=0.809

Primary: The Degree of Effectiveness of Acceptance and Commitment Therapy: [Impact] — 23.9; 21.4; 41.7; 37.5 units on a scale — p=0.82

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 7.2; 9.5 percent improvement — p=0.2735

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 10.7; 4.5 percent improvement — p=0.0854

Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale

Primary: Proportion of Non-Responder (NR) Participants — 14; 18; 14; 11 participants

Primary: The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment. — -1.32; -0.93; -0.73 units on a scale — p=0.014

Primary: Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment — 0.5; 0.5 units on a scale — p=0.9173

Primary: Overall Intervention Adherence Rate — 15.75 EMA App Surveys

Primary: Numerical Rating Scale (NRS) — 3.91; 3.87 scores on a scale

Primary: Percentage of Cancer Participants With Breakthrough Cancer Pain From the Total Number of Cancer Participants Seen in Consultation — 14.3 percentage of participants

Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325

Primary: Number of Participants With Reduction in Worst Pain Intensity or Reduction in 24hr Opioid Dose of at Least 30% Without Worsening of Pain Scores — 1; 2; 2; 1 Participants

Primary: Feasibility of Mobile Application Assessed by Observing the Number of Daily Pain Assessments Recorded Among Patients — 2.37 pain assessments per day

Primary: Self-reported Pain Score — -0.3 score on a scale, measured each week

Primary: Effect of Change of 20 rTMS Sessions on Pain — 5.53; 1.60; 1.97; 3.48 score on a scale

Primary: Pain Severity as Measured by the Brief Pain Inventory (BPI) — 4.71; 4.51; 3.52; 4.69 score on a scale

Primary: Overall Pain Relief. — 1.9; 0.5 score on a scale

Primary: Self-reported Change in Pain-related Disability — 4.22; 5.53 score on a scale — p=0.5163

Primary: Percentage of Participants With Maximum Pain Level Decreased by ≥ 2 Points at 2 Months After Radiofrequency Ablation (RFA) — 83.6 percentage of participants

Primary: Pain — 0; 0; 0; 0 units on a scale

Primary: Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine — 6.54; 0.25; 4.06 score on a scale

Primary: Feasibility of Intervention — 41; 17; 11; 5 Participants

Primary: Patient's Change From Baseline of Pain Severity, as Measured by the Weekly Means of the Daily Average Pain Scores (APS) — 2.26 units on a scale

Primary: Numeric Rating of Scale (From 0 to 10) of Pain and Possible Side Effects (Drowsiness, Confusion, Nausea) of Opioids — 2.22; 3.10; 2.83; 3.05 scores